Publication:
The Boston Scleral Lens in the Treatment of Pediatric Patients

dc.authorscopusid8540670700
dc.authorscopusid56823456100
dc.authorscopusid7102734556
dc.authorscopusid56903574700
dc.contributor.authorGüngör, I.
dc.contributor.authorSchor, K.
dc.contributor.authorRosenthal, P.
dc.contributor.authorJacobs, D.S.
dc.date.accessioned2020-06-21T15:13:43Z
dc.date.available2020-06-21T15:13:43Z
dc.date.issued2008
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Güngör] Inci Ulu, Boston Foundation for Sight, Needham, MA, United States, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Schor] Kenneth, Boston Foundation for Sight, Needham, MA, United States, Mount Sinai School, Cabrini Medical Center, New York, NY, United States; [Rosenthal] Perry, Boston Foundation for Sight, Needham, MA, United States, Harvard Medical School, Boston, MA, United States; [Jacobs] Deborah S., Boston Foundation for Sight, Needham, MA, United States, Harvard Medical School, Boston, MA, United Statesen_US
dc.description.abstractPurpose: To report the use of a custom-designed, fluid-ventilated, gas-permeable scleral lens in the treatment of patients under 13 years of age. Methods: We retrospectively reviewed the medical records of all patients under 13 years of age who were fitted with the Boston Scleral Lens at the Boston Foundation for Sight from January 1996 through June 2006. Age, sex, ophthalmic diagnosis, systemic diagnosis, prior surgical intervention, complications, lens fit and wearing failures, and duration of lens use are reported. Results: Boston Scleral Lenses were fitted in 47 eyes of 31 patients referred after failure of conventional therapy. Patients ranged in age from 7 months to 12.92 years (mean, 7.75 years) at time of fitting. There were 16 girls and 15 boys in this group. The mean duration of documented scleral lens use was 24 months (range, 0-85 months). A broad range of refractive and ocular surface disorders was treated with this modality, with the vast majority of patients having ocular surface disease (27/31, 87%) rather than refractive disorders (4/31, 13%). Congenital corneal anesthesia syndromes and Stevens-Johnson syndrome each accounted for over one-third of the patients. Conclusions: The Boston Scleral Lens is a custom-designed, fluid-ventilated, rigid gas-permeable scleral lens that vaults the cornea retaining a pool of oxygenated artificial tears over the corneal surface. The Boston Scleral Lens is a treatment option, after failure of conventional therapy, for a broad range of ocular surface and refractive disorders in the pediatric age group. Pediatric ophthalmologists should be aware of this treatment modality, particularly in the management of severe ocular surface disease. © 2008 American Association for Pediatric Ophthalmology and Strabismus.en_US
dc.identifier.doi10.1016/j.jaapos.2007.11.008
dc.identifier.endpage267en_US
dc.identifier.issn1091-8531
dc.identifier.issn1528-3933
dc.identifier.issue3en_US
dc.identifier.pmid18258469
dc.identifier.scopus2-s2.0-45549086487
dc.identifier.scopusqualityQ2
dc.identifier.startpage263en_US
dc.identifier.urihttps://doi.org/10.1016/j.jaapos.2007.11.008
dc.identifier.urihttps://hdl.handle.net/20.500.12712/19296
dc.identifier.volume12en_US
dc.identifier.wosWOS:000257556100010
dc.identifier.wosqualityQ3
dc.language.isoenen_US
dc.publisherMosby-Elsevieren_US
dc.relation.ispartofJournal of Aaposen_US
dc.relation.journalJournal of Aaposen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleThe Boston Scleral Lens in the Treatment of Pediatric Patientsen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files